BPH Global Targets Beverage Manufacturers With Seaweed Kefir Powder Deal

BPH Global strikes Singapore Polytechnic deal to develop seaweed kefir powder for beverage manufacturers

BPH Global (ASX: BP8), through its wholly owned Singapore subsidiary Stemcell United Pte Ltd, has executed an agreement with Singapore Polytechnic’s Food Innovation & Resource Centre (FIRC) to develop a freeze-dried powdered green seaweed kefir additive. The project represents a strategic evolution from finished beverage products toward an ingredient-based commercial model, targeting bottled water, alcoholic, and non-alcoholic beverage manufacturers. The total project cost is approximately S$15,260 (including GST), with FIRC providing approximately 100 man hours of technical services across a 12-month term.

Managing Director Matthew Leonard

“This agreement represents a strategic evolution toward an ingredient-based commercial model. By developing a powdered kefir additive, we are enabling beverage manufacturers to incorporate seaweed-derived nutraceutical benefits into their products in a scalable and commercially attractive way. This significantly broadens our addressable market beyond standalone beverages and positions the Company within the growing functional ingredients sector.”

From liquid beverage to functional ingredient — what this shift means

What is seaweed kefir and why does the powder format matter?

Probiotic green seaweed kefir is a fermented liquid product derived from green seaweed, containing live probiotic cultures and postbiotic compounds produced during fermentation. It differs from standard dairy-based kefir in that the fermentation substrate is seaweed rather than milk, delivering a distinct set of bioactive compounds associated with the nutritional properties of seaweed-derived nutraceuticals.

Freeze-drying is a process that removes moisture from the fermented liquid under low temperature and pressure, converting it into a stable powder while preserving its functional properties. This method is widely used in food and pharmaceutical manufacturing precisely because it maintains the integrity of sensitive biological components that would otherwise degrade.

The powdered format carries several commercial advantages over the liquid form:

• Long shelf life, reducing spoilage risk across supply chains
• Transport efficiency, lowering logistics costs compared to liquid products
• Scalability, enabling larger production volumes without proportional cost increases
• Easier integration into existing product lines for beverage and food manufacturers

Why the ingredient model is commercially significant

Supplying a powdered kefir additive rather than a finished beverage fundamentally changes who BPH Global’s customer is. Rather than marketing directly to end consumers, the company would supply manufacturers, who integrate the ingredient into their own established products and distribution networks.

This broadens the addressable market considerably. Beverage manufacturers in the bottled water, alcoholic, and non-alcoholic categories represent a large and established buyer base, and the company has noted that food product applications are also possible, though beverage-based applications remain the immediate focus. For investors, an ingredient-based model typically carries broader distribution reach and lower go-to-market friction compared to launching branded consumer products from scratch.

Agreement details and the road to proof-of-concept

The material terms of the FIRC agreement are summarised below.

With the agreement in place, the company has outlined four key next steps toward proof-of-concept (POC) validation:

1. Completion of freeze-drying trials and process optimisation
2. Validation of stability, dispersibility, and functional properties
3. Assessment of scalability and manufacturing pathways
4. Advancement of commercial partnership discussions

Preliminary discussions with potential venture and commercial partners are already underway to support downstream manufacturing and distribution, signalling early market interest in the powder’s commercial potential.

Investment thesis — broadening the addressable market

This new phase builds directly on a successfully completed R&D program with Singapore Polytechnic, which developed probiotic and postbiotic green seaweed kefir beverages. The seaweed kefir powder initiative is therefore a continuation of an established technical relationship, not a cold start, and the foundational science underpinning the formulation has already been validated through that prior work.

The near-term milestone that matters most is POC validation. A successful outcome would confirm the technical feasibility of the freeze-dried powder format and provide the foundation for substantive commercial partner conversations. The fact that preliminary discussions are already active ahead of that validation suggests a degree of market interest that warrants monitoring.

Intellectual property developed under the agreement is owned by the company, which positions any successfully validated formulation as a proprietary asset rather than a shared or licensed output. This is a meaningful consideration if the ingredient-based model progresses toward commercial scale.

By positioning the powdered kefir additive within the functional ingredients sector rather than the finished beverage category, BPH Global is targeting a meaningfully larger market opportunity. Investors should watch for POC validation outcomes and progress on commercial partnership discussions as the key catalysts over the 12-month agreement term.

Don’t Miss the Next Healthcare Breakout

Big News Blast delivers FREE breaking ASX healthcare and biotech news to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at Big News Blast to get the next market-moving announcement the moment it drops.